Eli Lilly extends clinical trials materials relationship

Five-year agreement involves Lilly's in-house clinical trial materials, including packaging and labeling operations.

Hp 19265 Eli Lilly Lab Shot
Biopharmaceutical company Eli Lilly reached a new five-year agreement with the Fisher Clinical Services business of ThermoFisher Scientific, with the latter taking over “responsibility for Lilly's in-house clinical trial materials manufacturing, packaging and labeling operations on-site at the Lilly Technology Center-North in Indianapolis,” according to a March 29 report on Trading Markets.com.

On its Web site, Eli Lilly's Ralph Lipp, PhD, vice president pharmaceutical sciences research and development, says, "Transitioning work like the manufacturing, packaging and labeling of clinical trial materials to Fisher Clinical Services helps us also reach Lilly's corporate goals of reducing the costs of drug development and speeding innovative medicines to patients."

-Jim Butschli, Editor
Companies in this article
More in Regulatory